The results of this study suggest that the incremental use of combinations of SGLT2 inhibitors, angiotensin-converting enzyme inhibitors–angiotensin receptor blockers, and β-blockers was associated with accumulative benefits in HF hospitalization rather than all-cause death among patients with HFpEF and HFmrEF. Here, SLC5A2 is linked to hydrops fetalis.